Science & Research
Tonix Pharmaceuticals Presents Preclinical Immuno-Oncology Data at AACR 2026, Highlighting Potential in Gastric Cancer and Immunotherapy
Tonix Pharmaceuticals announced new preclinical data for TNX-1700 and TNX-4700 at AACR 2026, showing potential in gastric cancer and as a BTLA-targeting immunotherapy, which could expand its oncology pipeline.
Helus Pharma Appoints Robert Langer and Stephen Brannan to Scientific Advisory Board, Bolstering Neuroscience Pipeline
Helus Pharma adds renowned experts Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board, strengthening its drug development capabilities for mental health treatments including major depressive disorder and generalized anxiety disorder.
Novel Urine Test May Predict Bladder Cancer Treatment Response
Researchers have developed a urine test that detects tumor DNA to predict residual bladder cancer after surgery and assess immunotherapy effectiveness.
American Heart Association Mourns Passing of Pioneering Cardiologist Eugene Braunwald
The American Heart Association honors the legacy of Dr. Eugene Braunwald, whose seven decades of research transformed cardiovascular medicine, and highlights his enduring influence through mentorship and the Eugene Braunwald Academic Mentorship Award.
Physical Activity May Be Safer Than Thought for Children with Certain Heart Conditions, New Statement Says
The American Heart Association's new scientific statement suggests that with proper evaluation and monitoring, physical activity can be beneficial for children with cardiomyopathies or implantable cardioverter-defibrillators, shifting away from blanket restrictions.
Soligenix's Platform Approach to Drug Development Offers Efficiency in Biopharmaceutical Innovation
Soligenix Inc. demonstrates how platform-based drug development using synthetic hypericin across multiple dermatologic conditions can streamline clinical impact and reduce redundancy in the biotech industry.
Powermax Minerals Reports Promising Rare Earth Element Findings in British Columbia
Powermax Minerals Inc. has identified significant rare earth element mineralization trends at its Cameron project in British Columbia, highlighting potential for North American critical mineral development amid growing global demand.
Loneliness Identified as Risk Factor for Degenerative Heart Valve Disease
New research reveals that loneliness, distinct from social isolation, is associated with a significantly higher risk of developing degenerative heart valve disease, suggesting it could be a modifiable risk factor with important implications for prevention and treatment strategies.
NeuroOne Partners with University of Minnesota to Advance Targeted Epilepsy Treatment Platform
NeuroOne Medical Technologies is collaborating with the University of Minnesota to develop a brain drug delivery system that could revolutionize epilepsy treatment by delivering therapies directly to seizure sites, potentially improving efficacy while reducing side effects.
American Heart Association Awards $15 Million to Research Early Detection of Heart Valve Disease
A new $15 million research initiative led by three major medical institutions aims to transform heart valve disease care by focusing on early detection and prevention strategies for a condition affecting over 80 million people worldwide.
NRx Pharmaceuticals Receives Positive FDA Review for Ketamine ANDA, Targets 2026 Approval
NRx Pharmaceuticals has received a positive FDA review letter for its ketamine ANDA and reported a supportive meeting with FDA leadership, advancing its preservative-free ketamine product toward potential approval in summer 2026 for treating severe mental illness.
Tonix Pharmaceuticals Publishes Pharmacokinetic Study Supporting TONMYA's Mechanism for Fibromyalgia Treatment
Tonix Pharmaceuticals' peer-reviewed study demonstrates TONMYA's superior pharmacokinetic profile compared to oral cyclobenzaprine, supporting its use as the first new fibromyalgia treatment in over 15 years.
Canadian Scientists Identify Brain Cells That Fuel Glioblastoma Growth
Researchers have discovered that certain brain cells previously thought to be passive support structures actively promote glioblastoma tumor growth, potentially opening new therapeutic avenues for one of the deadliest forms of brain cancer.
Kairos Pharma Recognized for Innovation in Overcoming Cancer Drug Resistance
Kairos Pharma Ltd. has been honored with the 2026 Pinnacle Award for its pioneering work on resistance-modulating treatments that aim to enhance the effectiveness of existing cancer therapies.
Analytical Validation Strengthens Soligenix Outlook as Pipeline Advances
A recent Zacks Small-Cap Research report highlights Soligenix's clinical progress and upcoming milestones, particularly in its phase 3 FLASH2 trial for cutaneous T-cell lymphoma treatment, reinforcing the company's strategic credibility and valuation potential.
Jacksonville Family Transforms Type 1 Diabetes Diagnosis Into Advocacy Through Community Initiative
A Jacksonville family's journey with their son's Type 1 diabetes diagnosis has evolved into Pablo's Pack T1D, a community initiative providing resources and support while participating in the Breakthrough T1D Walk to advance research toward a cure.
GeoVax Advances Mpox/Smallpox Vaccine Toward Phase 3 Trial Amid Global Supply Concerns
GeoVax Labs is preparing to initiate a pivotal Phase 3 trial for its GEO-MVA vaccine in the second half of 2026, addressing critical global supply constraints for orthopoxvirus vaccines while reporting a reduced net loss of $21.5 million for 2025.
Personalized mRNA Vaccine Shows Promise in Extending Pancreatic Cancer Survival
A personalized mRNA vaccine has demonstrated potential to meaningfully extend survival for pancreatic cancer patients, according to six-year trial results presented at a major oncology conference.
Generation Uranium Identifies High-Priority Drill Targets at Nunavut Project Using Proven Discovery Model
Generation Uranium has defined multiple high-impact drill targets at its Yath Uranium Project in Nunavut by applying exploration methodologies proven successful at the adjacent Angilak Project, positioning the company for its first-ever drilling campaign in one of Canada's most active uranium districts.
Memory Beads Inspired by 116-Year-Old's Habit Launch to Support Alzheimer's Research
A new tactile brain health tool called Peter's Memory Beads, inspired by a 116-year-old man's daily routine, has launched with all proceeds supporting Alzheimer's Association research and services.
NIMS Engineers Develop System to Track Material Design Processes, Enhancing AI Transparency and Reproducibility
Engineers at Japan's National Institute for Materials Science have developed a system called pinax that captures the entire trial-and-error process in material design, addressing critical challenges in reproducibility and accountability for AI-driven scientific discovery.
Soligenix Reports Positive Interim and Comparative Data for CTCL Treatment HyBryte
Soligenix announced consistent interim response rates from its phase 3 FLASH2 study and positive comparative results for HyBryte against Valchlor in cutaneous T-cell lymphoma, highlighting progress for a disease with limited treatment options.
Two Neuroscientists Awarded 2026 Ralph L. Sacco Scholarships for Brain Health Research
The American Academy of Neurology and the American Heart Association have awarded $150,000 scholarships to Sarah Kettlety and Cali McEntee to study concussion recovery in children and the effects of exercise on brain aging, respectively.
Combination Strategies Reshape Precision Oncology as Lixte Advances First-in-Class PP2A Inhibitor
Lixte Biotechnology's LB-100, a first-in-class PP2A inhibitor designed to enhance chemotherapy and immunotherapy, exemplifies the industry shift toward combination regimens to overcome resistance in solid tumors.
Soligenix Gains EU Orphan Drug Designation for SGX945 in Behçet's Disease, Bolstering Rare Disease Pipeline
The European Commission granted orphan drug designation to Soligenix's SGX945 for Behçet's disease, validating the therapy's potential and supporting the company's rare disease strategy.
LIXTE Biotechnology Advances LB-100 as a Novel Cancer Treatment Enhancer
LIXTE Biotechnology's LB-100, a first-in-class PP2A inhibitor, aims to boost the effectiveness of existing chemotherapies and immunotherapies in hard-to-treat cancers, with ongoing clinical trials for ovarian, colon, and soft tissue sarcomas.
Soligenix Reports Encouraging Interim Data and Positive Comparative Results for CTCL Therapy
Soligenix released promising interim analysis from its phase 3 FLASH2 study and positive comparative results for HyBryte versus Valchlor, reinforcing its progress in developing treatments for cutaneous T-cell lymphoma.
Precision Oncology Shifts to Combination Strategies as Resistance Challenges Persist
Cancer treatment is increasingly moving toward multi-drug regimens that combine targeted therapies with immunotherapy and chemotherapy, with Lixte Biotechnology's first-in-class PP2A inhibitor LB-100 designed to enhance existing treatments by disrupting cancer cell repair and boosting immune activity.
Ocumetics Reports Life-Changing Six-Month Results from First-in-Human Study of Accommodating Intraocular Lens
Ocumetics Technology Corp. announced that six-month postoperative results from its first-in-human study of the Ocumetics Accommodating Intraocular Lens show continued vision improvements and meaningful quality-of-life enhancements for patients, with plans to advance to Group Two surgeries.
Lantern Pharma Seeks FDA Feedback on HARMONIC Trial Protocol Amendments for Lung Cancer Drug
Lantern Pharma has scheduled a Type C meeting with the FDA to discuss proposed changes to its Phase 2 HARMONIC trial for LP-300 in non-small cell lung cancer, focusing on EGFR Exon 21 L858R patients based on promising clinical data.